76 reports

Targeted Therapies in Asthma: Update Bulletin ### [April 2018] This edition presents key opinion leader (KOL) views on recent developments in the Alzheimer’s Disease (AD) market.

  • Dementia
  • Mental Health
  • Pathology
  • Therapy

In this project, the researchers will study potential mechanisms for asthma development in two biological pathways where asthma genes and prenatal vitamin D and omega-## fatty acid supplementation supposedly operate to alter asthma risk.

  • Cancer
  • Dementia
  • Sweden
  • Karolinska Institutet Holding
  • Takeda Pharmaceutical Company Limited
  • 3.3 GLOBAL AND HISTORICAL TRENDS
  • 3.1 DISEASE BACKGROUND

Frontotemporal Degeneration, ##(##-##), pp. ##-##. doi: ##. ##/ ##. 2014. ##.

  • Dementia
  • Japan
  • United States
  • World
  • Forecast
  • 5.3 GLOBAL AND HISTORICAL TRENDS
  • 5.1 DISEASE BACKGROUND

We can use the Milano one, but we mainly use the King' s one. "

  • Dementia
  • Therapy
  • United States
  • Forecast
  • Ionis Pharmaceuticals, Inc.
  • NEURODEGENERATIVE DISORDERS THERAPEUTICS MARKET, COMORBIDITIES ASSOCIATED WITH

CNS Drugs; ##(##): ##-## Götz J, et al. (2008).

  • Dementia
  • World
  • Biogen Idec Inc.
  • Novartis AG
  • Roche Group
  • Alzheimer's Disease Drugs Sales Volume

High blood pressure and anxiety as well as other respiratory problems like asthma, bronchitis, and poor circulation.

  • Dementia
  • China
  • Trade
  • Janssen Biotech, Inc.
  • Xian-Janssen Pharmaceutical Ltd.
  • Alzheimer's Disease Drugs Sales Volume
  • Alzheimer's Disease Drugs Sales Volume

High blood pressure and anxiety as well as other respiratory problems like asthma, bronchitis, and poor circulation.

  • Dementia
  • China
  • Demand
  • Guizhou Yibai Pharmaceutical Co., Ltd.
  • Kunming Longjin Pharmaceutical Co Ltd
  • 12.1 BIBLIOGRAPHY

A FOOD AND DRUG ADMINISTRATION-APPROVED ASTHMA THERAPEUTIC AGENT IMPACTS AMYLOID Β CHEMISTRY; ##(##): 1966-1978.

  • Dementia
  • Allergan plc
  • Biogen Idec Inc.
  • Eisai Co., Ltd.
  • Novartis AG

Drivers and their Impact Impact on Key Customer Segments Driver Unmet Medical Needs Increase in Patient Population Low Low ## ## ## ## ## High High Hospitals ## ## ## ## ## Promising Drug Pipeline Special Provision for Rare Diseases Low Low ## ## ## ## ## High High ## ## ## ## ##

  • Dementia
  • Biogen Idec Inc.
  • Merck Serono S.A.
  • Novartis AG
  • Pfizer Inc.
  • 4.3.4 AZD3293 - ASTRAZENECA

In addition to mild-to-moderate AD, masitinib is being trialed for multiple sclerosis, asthma and various cancers.

  • Dementia
  • East Asia
  • World
  • Forecast
  • Biogen Idec Inc.
  • Alzheimer's Disease Market, Global, AZD3293 Market Forecast ($m), 2019-2021
  • 5.4.4 AB1010 - AB SCIENCE

Besides mild-to-moderate AD, masitinib is being trialed for multiple sclerosis, asthma and various cancers.

  • Dementia
  • World
  • Forecast
  • Market Size
  • Eisai Co., Ltd.
  • PRODUCT PROFILE - AB-1010

ALZHEIMER' S & DEMENTIA; ##(##): ##-##.

  • Dementia
  • Market Size
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Roche Group

Each security is composed of one ordinary share and one warrant.

  • Dementia
  • Pharmaceutical
  • Therapy
  • Europe
  • AB Science SA

IT AFFECTS ## IN ##, ## TO ## IN ##, ## BIRTHS.

  • Clinical Trial
  • Dementia
  • Hospital
  • Nucleic Acid
  • GlobalData's company
  • Amyotrophic Lateral Sclerosis
  • MASITINIB - DRUG PROFILE

It is also developing new approaches to the treatment of asthma.

  • Dementia
  • Therapy
  • United States
  • Product Initiative
  • AB Science SA
  • PIPELINE BY AB SCIENCE SA, H2 2018
  • saracatinib difumarate

ALS patients received riluzole plus masitinib ##. ## mg/ kg/ day, ##. ## mg/ kg/ day, or placebo (##:##:##) up to ## weeks.

  • Dementia
  • Therapy
  • United States
  • Product Initiative
  • AB Science SA

It effects from ## in ## to ## in 2000 people worldwide.

  • Clinical Trial
  • Dementia
  • Prostate Cancer
  • United States
  • GlobalData's company
  • NEFLAMAPIMOD - DRUG PROFILE

It is also developing new approaches to the treatment of asthma.

  • Dementia
  • Pharmaceutical
  • Therapy
  • United States
  • Product Initiative
  • NEFLAMAPIMOD - DRUG PROFILE

It is also developing new approaches to the treatment of asthma.

  • Dementia
  • Therapy
  • United States
  • Product Initiative
  • Synovo GmbH
  • registered with U.S. National Institutes of Health.
  • MASITINIB - DRUG PROFILE

This patent, which expires in 2032 protects to the use of masitinib in the treatment of severe persistent corticosteroid-dependent asthma and severe persistent corticosteroid-resistant asthma.

  • Dementia
  • Neurological Disorder
  • United States
  • Product Initiative
  • AB Science SA
  • PIPELINE BY LES LABORATOIRES SERVIER SAS, H1 2018
  • PIPELINE BY ONO PHARMACEUTICAL CO LTD, H1 2018

Its product portfolio includes pharmaceuticals for the treatment of diseases such as type II diabetes, overactive bladder, osteoporosis, Alzheimer' s disease, peripheral circulatory disorder, bronchial asthma and allergic rhinitis, among others.

  • Dementia
  • Mental Health
  • Therapy
  • World
  • Product Initiative

The company reported one pharmaceuticals & healthcare deal each in 2016 and 2017.

  • Dementia
  • Therapy
  • Switzerland
  • Company
  • Neurimmune
  • PIPELINE BY ACTINOGEN MEDICAL LTD, H1 2018

It is also developing new approaches to the treatment of asthma.

  • Dementia
  • United Kingdom
  • World
  • Product Initiative
  • Actinogen Limited

Presented post approval study results at the American Thoracic Society International Conference that demonstrated the Alair™ Bronchial Thermoplasty System reduced complications, including severe asthma exacerbations and asthma-related hospitalizations, in adult patients with severe

  • Clinical Trial
  • Dementia
  • Pathology
  • Therapy
  • GlobalData's company
  • JAN 08, 2018: $1.8 MILLION IN NEW FUNDING SUPPORTS CLINICAL STAGE TREATMENTS

Olichney and an interdisciplinary team of researchers at UC Davis have identified an existing KCa##. ## blocker called Senicapoc, which had excellent safety and tolerability in prior clinical trials for sickle cell anemia and asthma.

  • Dementia
  • Pharmaceutical
  • United States
  • Deals & Alliance
  • AGENEBIO INC.
  • Deal Type
  • ADC THERAPEUTICS RAISES USD105 MILLION IN PRIVATE PLACEMENT OF SHARES

It is also developing new approaches to the treatment of asthma.

  • Dementia
  • Pharmaceutical
  • Therapy
  • United States
  • ADC Therapeutics SA
  • ALZHEIMER'S DISEASE - PIPELINE BY PHARNEXT SA
  • ALZHEIMER'S DISEASE - PIPELINE BY PHARMAXIS LTD

One of these mechanisms, leukotriene signaling, is related to asthma.

  • Dementia
  • Pharmaceutical
  • United States
  • Company
  • Product Initiative
  • PIPELINE BY ASTRAZENECA PLC, H1 2018
  • PIPELINE BY H. LUNDBECK AS, H1 2018

It is also developing new approaches to the treatment of asthma.

  • Dementia
  • United States
  • Company Operations
  • Product Initiative
  • Eisai Co., Ltd.

It is also developing new approaches to the treatment of asthma.

  • Dementia
  • Pharmaceutical
  • Therapy
  • United States
  • Mitsubishi Corporation